Skip to content

Study · Randomized controlled trial · 2024

8 results

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.

Krumholz HM, de Lemos JA, Sattar N, Linetzky B, Sharma P, Mast CJ, Ahmad NN, Bunck MC, Stefanski A

Heart (British Cardiac Society)16 Sept 2024Cited by 30 (Europe PMC)

PMID39084707 (opens in a new tab)PMCIDPMC11420724 (opens in a new tab)DOI10.1136/heartjnl-2024-324170 (opens in a new tab)PepBankPUB-39084707
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, tirzepatide reduced systolic blood pressure by a net 6.8 mm Hg versus placebo at 72 weeks.

    In plain wordsIn adults with obesity or overweight, systolic blood pressure fell more with tirzepatide than with placebo over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure net reduction at week 72
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Net systolic blood pressure reduction
    6.8 mm Hg
    tirzepatide vs placebo, week 72

    Source sentences

    Summary
    Tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diast…
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, tirzepatide reduced diastolic blood pressure by a net 4.2 mm Hg versus placebo at 72 weeks.

    In plain wordsIn adults with obesity or overweight, diastolic blood pressure fell more with tirzepatide than with placebo over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiastolic blood pressure net reduction at week 72
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Net diastolic blood pressure reduction
    4.2 mm Hg
    tirzepatide vs placebo, week 72

    Source sentences

    Summary
    Tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diast…
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, tirzepatide was associated with a rapid decline in blood pressure over the first 24 weeks, followed by stabilisation.

    In plain wordsIn adults with obesity or overweight, blood pressure fell quickly with tirzepatide over 24 weeks, then stayed steady.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTime course of blood pressure reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diast…
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, more people on any tirzepatide dose than on placebo had normal blood pressure at week 72.

    In plain wordsIn adults with obesity or overweight, more people on tirzepatide than on placebo had normal blood pressure after 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion with normal blood pressure at week 72
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Proportion with normal blood pressure
    58%
    tirzepatide
    Proportion with normal blood pressure
    35.2%
    placebo

    Source sentences

    Summary
    Participants randomly assigned to any tirzepatide group were more likely than those assigned to placebo to have normal blood pressure at week 72 (58.0% vs 35.2%, respectively).
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, the blood pressure effects of tirzepatide were broadly consistent across baseline blood pressure subgroups.

    In plain wordsIn adults with obesity or overweight, tirzepatide lowered blood pressure in a similar way across starting blood pressure groups.

    Peptide
    Tirzepatide
    Outcome
    DecreaseConsistency of blood pressure effect across baseline blood pressure subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The effects were broadly consistent across baseline blood pressure subgroups, shifting the blood pressure distribution curve to lower blood pressure levels.
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  6. 06HumanRandomized controlled trialMechanism

    In adults with obesity or overweight, mediation analysis indicated weight loss explained 68% of the systolic blood pressure reduction with tirzepatide.

    In plain wordsIn adults with obesity or overweight, weight loss explained about two thirds of the systolic blood pressure drop with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableShare of systolic blood pressure reduction explained by weight loss
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Proportion mediated by weight loss
    68%
    systolic blood pressure

    Source sentences

    Summary
    The mediation analysis indicated that weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction.
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  7. 07HumanRandomized controlled trialMechanism

    In adults with obesity or overweight, mediation analysis indicated weight loss explained 71% of the diastolic blood pressure reduction with tirzepatide.

    In plain wordsIn adults with obesity or overweight, weight loss explained about seven tenths of the diastolic blood pressure drop with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableShare of diastolic blood pressure reduction explained by weight loss
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Proportion mediated by weight loss
    71%
    diastolic blood pressure

    Source sentences

    Summary
    The mediation analysis indicated that weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction.
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.
  8. 08HumanRandomized controlled trialSafety outcome

    In adults with obesity or overweight, low blood pressure adverse events were infrequent but occurred at a higher rate with tirzepatide than with placebo.

    In plain wordsIn adults with obesity or overweight, low blood pressure side effects were uncommon but more frequent with tirzepatide than with placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseLow blood pressure adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Low blood pressure adverse events were infrequent, but the rate was higher in the tirzepatide group.
    1 context sentence
    Summary · context
    In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07573163

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Alaa Sadan = 3427 Jul 2026 to est. 31 Dec 2028

Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status

Trial pageClinicalTrials.govUpdated 30 Jul 2026
CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.